| Literature DB >> 30267178 |
Motoi Azumi1, Manabu Takeuchi2, Youhei Koseki1, Masaru Kumagai1, Yoko Kobayashi1, Masafumi Takatsuna1, Aiko Yoshioka1, Seiichi Yoshikawa1, Tsutomu Miura1, Shuji Terai3.
Abstract
BACKGROUND: Delayed bleeding is an important complication after gastric endoscopic submucosal dissection (ESD). The search, coagulation, and clipping (SCC) method can be used to prevent delayed bleeding after ESD. However, its safety and efficacy are unclear. We compared the SCC method with post-ESD coagulation (PEC) to clarify the safety and efficacy of the SCC method for preventing delayed bleeding after gastric ESD.Entities:
Keywords: Clip; Delayed bleeding; Gastric endoscopic submucosal dissection
Mesh:
Substances:
Year: 2018 PMID: 30267178 PMCID: PMC6476836 DOI: 10.1007/s10120-018-0878-y
Source DB: PubMed Journal: Gastric Cancer ISSN: 1436-3291 Impact factor: 7.370
Fig. 1a Blood vessel pre-coagulated during ESD is observed. It was thought to be a penetrating branch passing through the muscle layer. Thus, a clip was placed. b Blood vessel could not be identified during ESD but could be identified on observation using GIF-H260Z (Olympus, Tokyo, Japan). The blood vessel is small, but a pulse was detected. Thus, it was diagnosed as an artery, and a clip was placed. ESD endoscopic submucosal dissection
Fig. 2a Post-ESD ulcer after completion of the PEC method. PEC post-endoscopic submucosal dissection coagulation. b Post-ESD ulcer after completion of the SCC method. SCC search, coagulation, and clipping, ESD endoscopic submucosal dissection
Patient, lesion, and procedure characteristics
| Variable | Category | Distribution |
|---|---|---|
| Patient characteristics | ||
| Number, | 438 | |
| Age (years) | ||
| Median (range) | 73 (41–94) | |
| Sex, | ||
| Male | 323 (73.7) | |
| Female | 115 (26.3) | |
| Antithrombotic agents, | ||
| None | 360 (82.2) | |
| Warfarin | 9 (2.1) | |
| DOAC | 12 (2.7) | |
| Antiplatelet therapy | 47 (10.7) | |
| Others | 10 (2.3) | |
| Lesion characteristics | ||
| Location, | ||
| Upper | 183 (41.8) | |
| Middle | 191 (43.6) | |
| Lower | 64 (14.6) | |
| Specimen size (mm) | ||
| Median (range) | 35 (15–105) | |
| Specimen size, | ||
| ≥ 40 mm | 165 (37.7) | |
| > 40 mm | 273 (62.3) | |
| Histological type, | ||
| Adenocarcinoma | 401 (91.5) | |
| Adenoma | 27 (6.2) | |
| Others | 10 (2.3) | |
| Depth, | ||
| Intramucosa | 390 (89) | |
| Submucosa | 48 (11) | |
| Tumor size (mm) | ||
| 15 (0–100) | ||
| Macroscopic type, | ||
| Depressed | 213 (51.4) | |
| Non-depressed | 225 (48.6) | |
| Ulceration, | ||
| Negative | 404 (92.2) | |
| Positive | 34 (7.8) | |
| HM, | ||
| Negative | 435 (99.3) | |
| Positive | 3 (0.7) | |
| VM, | ||
| Negative | 432 (98.6) | |
| Positive | 6 (1.4) | |
| ly, | ||
| Negative | 427 (97.5) | |
| Positive | 11 (2.5) | |
| v, | ||
| Negative | 430 (98.2) | |
| Positive | 8 (1.8) | |
| Procedure characteristics | ||
| Procedure time (min) | ||
| Median (range) | 84 (10–461) | |
| Time of SCC (s) | ||
| Median (range) | 297 (38–1075) | |
| Heparin placement | ||
| Without | 424 (96.8) | |
| With | 14 (3.2) | |
| Second-look endoscopy | ||
| Additional coagulation | ||
| Without | 421 (96.1) | |
| With | 17 (3.9) | |
| Additional clipping | ||
| Without | 429 (97.7) | |
| With | 9 (2.3) | |
| Perforation during ESD, | ||
| Negative | 431 (98.4) | |
| Positive | 7 (1.6) | |
| Post-ESD stenosis, | ||
| Negative | 434 (99.1) | |
| Positive | 4 (0.9) | |
DOAC direct oral antithrombotic agent, HM horizontal margin, VM vertical margin, ly lymphatic invasion, v venous invasion, ESD endoscopic submucosal dissection, SCC search, coagulation, and clipping
Comparison of the PEC and SCC groups
| Variable | PEC group | SCC group | |
|---|---|---|---|
| ( | ( | ||
| Delayed bleeding, | |||
| Negative | 200 (92.8) | 217 (97.4) | 0.013a |
| Positive | 16 (7.2) | 5 (2.6) | |
| Number of clips, | |||
| Mean (SD) | 0 | 4.87 (2.28) | |
| Median (range) | 0 | 4.0 (1–12) | < 0.001b |
| Age (years) | |||
| Median (range) | 73.0 (46–91) | 74.0 (41–94) | 0.688b |
| Sex, | |||
| Male | 153 (70.8) | 131 (59.0) | 0.172a |
| Female | 63 (29.2) | 91 (41.0) | |
| Antithrombotic agents, | |||
| None | 173 (80.1) | 187 (84.2) | 0.279a |
| Warfarin | 6 (2.8) | 3 (1.4) | |
| DOAC | 6 (2.8) | 6 (2.7) | |
| Antiplatelet therapy | 23 (10.6) | 24 (10.8) | |
| Others | 8 (3.7) | 2 (0.9) | |
| Delayed bleeding in patients who received antithrombotic agents (%) | |||
| 11.6 | 5.7 | 0.31c | |
| Location, | |||
| Upper | 97 (44.9) | 86 (38.7) | 0.409a |
| Middle | 88 (40.7) | 103 (46.4) | |
| Lower | 31 (14.4) | 33 (14.9) | |
| Specimen size (mm) | |||
| Median (range) | 32 (15–90) | 35(16–105) | 0.013b |
| Specimen size, | |||
| ≥ 40 mm | 142 (65.7) | 131 (59.0) | 0.146b |
| > 40 mm | 74 (34.3) | 91 (41.0) | |
| Tumor size (mm) | 12 (0–65) | 15 (0–100) | < 0.001b |
| Ulceration, | |||
| Negative | 209 (99.7) | 195 (87.9) | < 0.001a |
| Positive | 7 (0.30) | 27 (12.1) | |
| Procedure time (min) | |||
| Median (range) | 65.5 (9–357) | 84.0 (10–461) | 0.01b |
| Heparin placement | |||
| Without | 212 (96.3) | 216 (97.3) | 0.305a |
| With | 8 (3.7) | 6 (2.7) | |
| Second-look endoscopy | |||
| Additional coagulation | |||
| Without | 206 (95.4) | 215 (96.8) | 0.672a |
| With | 10 (4.6) | 7 (3.2) | |
| Additional clipping | |||
| Without | 213 (97.7) | 216 (97.3) | 0.400a |
| With | 3 (2.3) | 6 (2.7) | |
| Perforation during ESD, | |||
| Negative | 213 (98.6) | 218 (98.2) | 0.676a |
| Positive | 3 (1.4) | 4 (1.8) | |
| Post-ESD stenosis, | |||
| Negative | 214 (99.1) | 216 (99.1) | 0.978a |
| Positive | 2 (0.9) | 2 (0.9) | |
PEC post-ESD coagulation, SCC search, coagulation, and clipping, SD standard deviation, DOAC direct oral antithrombotic agent, ESD endoscopic submucosal dissection
aChi-square test
bMann–Whitney U test
cFisher’s exact test
Multivariate analysis for the factors associated with delayed bleeding after ESD
| Variable | Estimated regression coefficient | SE | OR (95% CI) | |
|---|---|---|---|---|
| SCC method | − 1.24 | 0.522 | 0.289 (0.104–0.804) | 0.017 |
ESD endoscopic submucosal dissection, SE standard error of the regression coefficient, OR odds ratio, CI confidence interval, SCC search, coagulation, and clipping
aWald test
Comparison of the PEC and SCC groups after propensity-score-matching analysis
| Variables | PEC ( | SCC ( |
|
|---|---|---|---|
| Delayed bleeding | |||
| Negative | 142 (92.3) | 152 (97.3) | 0.0130a |
| Positive | 14 (7.7) | 4 (2.6) | |
| Age | 72 (46–91) | 75 (41–94) | 0.0670b |
| Sex | |||
| Male | 112 (71.8) | 118 (75.6) | 0.2600c |
| Female | 44 (28.2) | 38 (24.4) | |
| Antithrombotic agents | |||
| None | 130 (83.3) | 131 (84.0) | 0.6900c |
| Warfarin | 2 (1.3) | 2 (1.3) | |
| DOAC | 6 (3.8) | 2 (1.3) | |
| Antiplatelet therapy | 17 (10.9) | 20 (12.8) | |
| Others | 1 (0.6) | 1 (0.6) | |
| Location | |||
| Upper | 64 (41.0) | 63 (40.4) | 0.7040c |
| Middle | 73 (46.8) | 69 (44.2) | |
| Lower | 19 (12.2) | 24 (15.4) | |
| Specimen size | 35 (15–90) | 35 (16–88) | 0.7650b |
| Specimen size 40 | |||
| < 40 | 99 (63.5) | 99 (64.6) | 0.5470c |
| ≥ 40 | 57 (36.5) | 57 (35.4) | |
| Tumor size | 12 (0–65) | 15 (0–77) | 0.0607b |
| Procedure time | 72.0 (9–357) | 80.0 (10–350) | 0.2890b |
| Heparin placement | |||
| Without | 152 (96.2) | 153 (98.1) | 0.2510a |
| With | 6 (3.8) | 3 (1.9) | |
PEC post-ESD coagulation, SCC search, coagulation, and clipping, SD standard deviation, DOAC direct oral antithrombotic agent, ESD endoscopic submucosal dissection
aFisher’s exact test
bMann–Whitney U test
cChi-square test
Details of the 21 patients with delayed bleeding
| Patient | Procedure | Timing of delayed bleeding | Transfusion | Readmission | Cost of readmission | Antithrombotic agent | Heparin placement |
|---|---|---|---|---|---|---|---|
| (USD/JPY) | |||||||
| 1 | PEC | Day 5 | Warfarin | + | |||
| 2 | PEC | Day 15 | + | (2542/279,780) | DOAC | + | |
| 3 | PEC | Day 15 | + | + | (6531/718,820) | DOAC, aspirin | |
| 4 | PEC | Day 14 | + | (5366/590,610) | DOAC | ||
| 5 | PEC | Day 7 | + | (5254/578,270) | |||
| 6 | PEC | Day 11 | + | (2814/309,790) | |||
| 7 | PEC | Day 5 | |||||
| 8 | PEC | Day 7 | DOAC | + | |||
| 9 | PEC | Day 6 | |||||
| 10 | PEC | Day 11 | + | + | (5679/625,110) | ||
| 11 | PEC | Day 1 | |||||
| 12 | PEC | Day 1 | |||||
| 13 | PEC | Day 6 | + | + | (2134/234,910) | ||
| 14 | PEC | Day 10 | + | (2566/282,480) | |||
| 15 | PEC | Day 0 (6 h) | |||||
| 16 | PEC | Day 2 | |||||
| 17 | SCC | Day 15 | + | + | (4386/482,730) | ||
| 18 | SCC | Day 10 | + | + | (2971/327,010) | Dual-antiplatelet therapy | |
| 19 | SCC | Day 7 | + | (2556/281,370) | |||
| 20 | SCC | Day 10 | + | + | (4749/522,700) | ||
| 21 | SCC | Day 9 | + | + | (4280/471,090) |
PEC post-endoscopic submucosal dissection coagulation, DOAC direct oral antithrombotic agent, SCC search, coagulation, and clipping